143 related articles for article (PubMed ID: 28230750)
1. Targeting MDM4 Splicing in Cancers.
Bardot B; Toledo F
Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28230750
[TBL] [Abstract][Full Text] [Related]
2. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F
Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193
[TBL] [Abstract][Full Text] [Related]
3. Identification and expression of a novel MDM4 splice variant in human glioma.
Wang X; Sheng P; Guo X; Wang J; Hou L; Hu G; Luo C; Dong Y; Lu Y
Brain Res; 2013 Nov; 1537():260-6. PubMed ID: 23994448
[TBL] [Abstract][Full Text] [Related]
4. MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Wu J; Lu G; Wang X
Am J Cancer Res; 2021; 11(12):5864-5880. PubMed ID: 35018230
[TBL] [Abstract][Full Text] [Related]
5. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
6. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
7. Tumorigenesis promotes Mdm4-S overexpression.
Pant V; Larsson CA; Aryal N; Xiong S; You MJ; Quintas-Cardama A; Lozano G
Oncotarget; 2017 Apr; 8(16):25837-25847. PubMed ID: 28460439
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.
Dewaele M; Tabaglio T; Willekens K; Bezzi M; Teo SX; Low DH; Koh CM; Rambow F; Fiers M; Rogiers A; Radaelli E; Al-Haddawi M; Tan SY; Hermans E; Amant F; Yan H; Lakshmanan M; Koumar RC; Lim ST; Derheimer FA; Campbell RM; Bonday Z; Tergaonkar V; Shackleton M; Blattner C; Marine JC; Guccione E
J Clin Invest; 2016 Jan; 126(1):68-84. PubMed ID: 26595814
[TBL] [Abstract][Full Text] [Related]
10. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
11. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
12. MDM4 (MDMX) and its Transcript Variants.
Mancini F; Di Conza G; Moretti F
Curr Genomics; 2009 Mar; 10(1):42-50. PubMed ID: 19721810
[TBL] [Abstract][Full Text] [Related]
13. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
14. MDM4 Isoform Expression in Melanoma Supports an Oncogenic Role for MDM4-A.
Alatawi A; Kho S; Markey MP
J Skin Cancer; 2021; 2021():3087579. PubMed ID: 34697572
[TBL] [Abstract][Full Text] [Related]
15. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
16. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
[TBL] [Abstract][Full Text] [Related]
17. Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development.
Zhang Q; He X; Chen L; Zhang C; Gao X; Yang Z; Liu G
J Pathol; 2012 Nov; 228(3):416-28. PubMed ID: 22821713
[TBL] [Abstract][Full Text] [Related]
18. Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity.
Giglio S; Mancini F; Pellegrino M; Di Conza G; Puxeddu E; Sacchi A; Pontecorvi A; Moretti F
Oncogene; 2010 Nov; 29(44):5935-45. PubMed ID: 20697359
[TBL] [Abstract][Full Text] [Related]
19. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
Kriegmair MC; Balk M; Wirtz R; Steidler A; Weis CA; Breyer J; Hartmann A; Bolenz C; Erben P
Anticancer Res; 2016 Oct; 36(10):5205-5213. PubMed ID: 27798881
[TBL] [Abstract][Full Text] [Related]
20. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]